Sledge G - Search Results

1

A phase II study of methylphenidate for the treatment of fatigue.

Hanna A, Sledge G, Mayer ML, Hanna N, Einhorn L, Monahan P, Daggy J, Bhatia S. Hanna A, et al. Among authors: sledge g. Support Care Cancer. 2006 Mar;14(3):210-5. doi: 10.1007/s00520-005-0857-9. Epub 2005 Aug 12. Support Care Cancer. 2006. PMID: 16096772 Clinical Trial.

2

Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.

Sledge GW Jr, Einhorn L, Nagy C, House K. Sledge GW Jr, et al. Cancer. 1992 Nov 15;70(10):2524-8. doi: 10.1002/1097-0142(19921115)70:10<2524::aid-cncr2820701022>3.0.co;2-z. Cancer. 1992. PMID: 1423181 Clinical Trial.

3

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.

Munshi NC, Loehrer PJ Sr, Williams SD, Langefeld C, Sledge G, Nichols CR, Roth BJ, Neuman A, Walsh WB, Einhorn LH. Munshi NC, et al. Among authors: sledge g. Invest New Drugs. 1992 Aug;10(3):159-63. doi: 10.1007/BF00877240. Invest New Drugs. 1992. PMID: 1428725

4

Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group.

Roth BJ, Sledge GW Jr, Williams SD, Meyer SC, Ansari R, Fisher WB. Roth BJ, et al. Among authors: sledge gw jr. Cancer. 1991 Jul 15;68(2):248-52. doi: 10.1002/1097-0142(19910715)68:2<248::aid-cncr2820680205>3.0.co;2-4. Cancer. 1991. PMID: 2070321 Clinical Trial.

5

Relation of proliferative activity to survival in patients with advanced germ cell cancer.

Sledge GW Jr, Eble JN, Roth BJ, Wuhrman BP, Fineberg N, Einhorn LH. Sledge GW Jr, et al. Cancer Res. 1988 Jul 1;48(13):3864-8. Cancer Res. 1988. PMID: 2837326

6

Cisplatin as first-line therapy for metastatic breast cancer.

Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH. Sledge GW Jr, et al. J Clin Oncol. 1988 Dec;6(12):1811-4. doi: 10.1200/JCO.1988.6.12.1811. J Clin Oncol. 1988. PMID: 3199166

7

5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group.

Roth BJ, Elson P, Sledge GW Jr, Einhorn LH, Trump DL. Roth BJ, et al. Among authors: sledge gw jr. Invest New Drugs. 1993 May-Aug;11(2-3):201-2. doi: 10.1007/BF00874155. Invest New Drugs. 1993. PMID: 7505269 Clinical Trial. No abstract available.

8

Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease.

Olivarez D, Ulbright T, DeRiese W, Foster R, Reister T, Einhorn L, Sledge G. Olivarez D, et al. Among authors: sledge g. Cancer Res. 1994 May 15;54(10):2800-2. Cancer Res. 1994. PMID: 7513256

9

Tandem autotransplantation for the treatment of metastatic breast cancer.

Broun ER, Sridhara R, Sledge GW, Loesch D, Kneebone PH, Hanna M, Hromas R, Cornetta K, Einhorn LH. Broun ER, et al. Among authors: sledge gw. J Clin Oncol. 1995 Aug;13(8):2050-5. doi: 10.1200/JCO.1995.13.8.2050. J Clin Oncol. 1995. PMID: 7636548 Clinical Trial.

10

High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer.

Broun ER, Sledge GW, Einhorn LH, Tricot GJ. Broun ER, et al. Among authors: sledge gw. Am J Clin Oncol. 1993 Feb;16(1):9-13. Am J Clin Oncol. 1993. PMID: 8424413 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

454 results

Search Page

Filters